Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

References

• Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. Lyon, France: IARC; 2008.
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040–2045. doi:https://doi.org/10.1182/blood-2010-03-276246.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(9):965–972. doi:https://doi.org/10.1016/j.bbmt.2006.05.018.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:https://doi.org/10.1182/blood-2017-03-769620.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, et al. A comparison of 2-year outcomes in ZUMA-1 (axicabtagene ciloleucel [axi-cel]) and SCHOLAR-1 in patients (Pts) with refractory large B cell lymphoma (LBCL). Biol Blood Marrow Transplant. 2020;26:S1–S412.
   PubMed Web of Science ®Google Scholar
• Calimeri T, Ferreri AJM. m-TOR inhibitors and their potential role in haematological malignancies. Br J Haematol. 2017;177(5):684–702. doi:https://doi.org/10.1111/bjh.14529.
   PubMed Web of Science ®Google Scholar
• Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol. 2006;134(5):475–484. doi:https://doi.org/10.1111/j.1365-2141.2006.06210.x.
   PubMed Web of Science ®Google Scholar
• Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia. 2007;21(2):333–339. doi:https://doi.org/10.1038/sj.leu.2404471.
   PubMed Web of Science ®Google Scholar
• Yee KWL, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12(17):5165–5173. [Database] doi:https://doi.org/10.1158/1078-0432.CCR-06-0764.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341–347. [Database] doi:https://doi.org/10.1038/leu.2010.226.
   PubMed Web of Science ®Google Scholar
• Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. 2008;36(4):443–450. doi:https://doi.org/10.1016/j.exphem.2007.12.008.
   PubMed Web of Science ®Google Scholar
• Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res. 2002;8(3):662–664.
   PubMed Web of Science ®Google Scholar
• Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007;121(5):1138–1148. doi:https://doi.org/10.1002/ijc.22751.
   PubMed Web of Science ®Google Scholar
• Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013;19(24):6882–6890. doi:https://doi.org/10.1158/1078-0432.CCR-13-1906.
   PubMed Web of Science ®Google Scholar
• Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood. 2012;119(17):4017–4025. doi:https://doi.org/10.1182/blood-2011-01-331421.
   PubMed Web of Science ®Google Scholar
• Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–194. doi:https://doi.org/10.1182/blood-2016-02-699520.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, Neuberg D, et al. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: results of a phase II study. Hematol Oncol. 2018;36(4):633–637. doi:https://doi.org/10.1002/hon.2515.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–1636. doi:https://doi.org/10.1038/leu.2013.38.
   PubMed Web of Science ®Google Scholar
• Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, et al. A phase I/II trial of panobinostat in combination with lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(6):347–353. doi:https://doi.org/10.1016/j.clml.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, et al. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2018;59(12):2904–2910. doi:https://doi.org/10.1080/10428194.2018.1452208.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:https://doi.org/10.1200/JCO.2006.09.2403.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98(4):615–619. doi:https://doi.org/10.3324/haematol.2012.075184.
   PubMed Web of Science ®Google Scholar
• Apuri S, Sokol L. An overview of investigational histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opin Investig Drugs. 2016;25(6):687–696. doi:https://doi.org/10.1517/13543784.2016.1164140.
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017;178(3):434–441. doi:https://doi.org/10.1111/bjh.14698.
   PubMed Web of Science ®Google Scholar